Induction alectinib or crizotinib for stage III NSCLC harboring ALK fusion: A study with 4-year follow-up.
Chinese medical journal
Zhang C, Liu S, Jiang B, Chen Z, Yan L, Qiu Z, Lin J, Yang X, Wu Y, Sun H, Zhong W.
Publication Overview
Key findings, Countstar context, and access to the original paper.
2026
Cancer Research
Single-Cell Analysis
No items found.
Key Finding
In patients with stage III ALK-positive NSCLC, induction ALK-TKI therapy enabled complete tumor resection with limited postoperative complications. Alectinib produced numerically higher major and complete pathological response rates than crizotinib and was associated with longer progression-free survival, supporting the strategy's clinical feasibility.
Countstar Connection
The study obtained cell-viability measurements from the study's cell samples using Countstar Altair during preparation for single-cell or single-nucleus analysis.
